Wegovy vs Mounjaro: Which Weight Management Option Suits You?
Wegovy and Mounjaro UK Stock Availability - No More Waiting
Unlike the supply shortages experienced across the UK pharmacy sector in recent years, EverydayMeds maintains consistent stock of both Wegovy and Mounjaro treatments. Our direct supply agreements with Novo Nordisk and Eli Lilly ensure all doses remain available for immediate dispatch. Wegovy stock includes 0.25mg starter pens through to 2.4mg maintenance doses, whilst Mounjaro covers the complete 2.5mg to 15mg range.
This reliable availability means you can begin your weight management journey immediately, whether your prescriber recommends Wegovy's proven semaglutide formula or Mounjaro's dual-action tirzepatide approach. Both treatments require prescription-only medicine approval, but our streamlined clinical assessment process typically delivers approvals within 24-72 hours, followed by next-day temperature-controlled delivery to your door.
Wegovy Mounjaro Pricing Comparison - Transparent UK Costs
Wegovy pricing starts at £79.99 for the 0.25mg starter dose, escalating to £209.99 for the 2.4mg maintenance pen. Our Getting Started bundles offer convenience - the Intro Duo (0.25mg & 0.5mg) costs £169.99, providing your first 8 weeks of treatment in a single order. New customers apply code FIRST40 at checkout, whilst returning customers use DOSE25 to access these competitive rates.
Mounjaro follows a different pricing structure reflecting its newer dual-agonist technology. Both treatments represent significant investments in your health, but our bundle options reduce the frequency of reordering whilst ensuring continuous supply. The Ultimate Stability Trio provides 3 months of maintenance Wegovy supply for £649.99, eliminating monthly prescription renewals and potential stock concerns during your weight management programme.
Clinical Evidence Behind Wegovy and Mounjaro Efficacy
In clinical trials, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks in the landmark STEP 1 study (Wilding et al., NEJM, 2021). The STEP programme demonstrated consistent results across different populations, with STEP 2 showing 9.6% weight reduction in patients with type 2 diabetes, whilst STEP 3 achieved 16% with intensive behavioural therapy.
Mounjaro's SURMOUNT trials demonstrated the potential of dual GIP/GLP-1 receptor activation, though direct comparison between trial results isn't appropriate due to different study designs and populations. Both medications require long-term commitment - STEP extension data showed patients regained approximately two-thirds of weight lost within one year of discontinuation, emphasising that weight management remains an ongoing clinical process.
Understanding How Wegovy and Mounjaro Work Differently
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural incretin hormone to reduce appetite and promote satiety after smaller meals. This single-target approach has extensive clinical validation and represents the gold standard for GLP-1-based weight management. Mounjaro uses tirzepatide, which activates both GLP-1 and GIP receptors simultaneously, creating dual pathways for metabolic regulation. Both medications work on brain appetite centres to potentially reduce food cravings, but their receptor targets and metabolic effects differ significantly. Your prescriber can help determine which mechanism aligns better with your individual clinical profile and weight management goals.
Streamlined Wegovy Mounjaro Ordering Process
Our 3-minute online clinical assessment captures essential medical history, current medications, and weight management goals to help prescribers determine suitability for either treatment. Standard prescriber review takes up to 3 working days, though express 24-hour review is available for urgent requirements. Once approved, both Wegovy and Mounjaro ship via next-day cold-chain delivery, maintaining the 2-8°C temperature requirements throughout transit. Payment processing occurs only after prescription approval, ensuring you're never charged for treatments that aren't medically appropriate. Our clinical team remains available for ongoing support throughout your dose escalation journey with either medication.
Storage and Practical Differences Between Wegovy and Mounjaro
Both treatments require refrigerated storage at 2-8°C before first use, but Wegovy offers superior travel convenience with 6 weeks of room temperature stability below 30°C once removed from the fridge. Mounjaro provides 21 days of room temperature storage, still generous but requiring more careful planning for extended trips. Wegovy uses Novo Nordisk's FlexTouch pen technology, whilst Mounjaro employs KwikPen devices - both are pre-filled, single-use injectors requiring weekly subcutaneous administration. The dose escalation schedules differ significantly: Wegovy follows a 16-week titration to 2.4mg maintenance, whilst Mounjaro typically escalates over 20 weeks to reach optimal therapeutic levels. Neither pen requires mixing or preparation beyond removing from refrigerated storage.
Wegovy Mounjaro Supply Chain Reliability in the UK Market
Supply disruptions have historically affected weight management medications across the UK, with Wegovy experiencing notable shortages during 2022-2023 following overwhelming demand. EverydayMeds has invested in supply chain partnerships and inventory management systems specifically to prevent these patient disruptions. Our direct pharmaceutical relationships ensure priority allocation during high-demand periods, whilst our cold storage facilities maintain optimal stock rotation for both treatments.
This supply reliability becomes crucial during your dose escalation phase - missing weekly injections can necessitate restarting the titration schedule from lower doses. Our automated prescription renewal reminders and inventory monitoring prevent treatment interruptions that could compromise your weight management progress. Both Wegovy and Mounjaro are available from EverydayMeds with the supply security you need for consistent long-term treatment.
Order Wegovy or Mounjaro Today - Expert Clinical Support Included
Whether semaglutide's proven single-target approach or tirzepatide's innovative dual-agonist mechanism suits your needs, both treatments are immediately available through our secure ordering platform at https://everydaymeds.co.uk/collections/wegovy. Use code FIRST40 for new customer pricing, or DOSE25 for returning patients. Our GPhC-registered pharmacy (#9012878) ensures full regulatory compliance, whilst our clinical team provides ongoing support throughout your treatment journey. Start your clinical assessment today and receive your chosen prescription-only medicine tomorrow with temperature-controlled delivery. Both Wegovy and Mounjaro represent evidence-based approaches to weight management - your prescriber can help determine which option aligns with your individual clinical requirements and lifestyle preferences.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
